KR20250008042A - Mglur5 조정 화합물, 조성물, 및 사용 방법 - Google Patents

Mglur5 조정 화합물, 조성물, 및 사용 방법 Download PDF

Info

Publication number
KR20250008042A
KR20250008042A KR1020247034686A KR20247034686A KR20250008042A KR 20250008042 A KR20250008042 A KR 20250008042A KR 1020247034686 A KR1020247034686 A KR 1020247034686A KR 20247034686 A KR20247034686 A KR 20247034686A KR 20250008042 A KR20250008042 A KR 20250008042A
Authority
KR
South Korea
Prior art keywords
compound
degrees
solvate
solvate form
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247034686A
Other languages
English (en)
Korean (ko)
Inventor
티모시 라이언 시거트
스티븐 스트릿매터
페데리코 스카라벨리
카밀라 코라
Original Assignee
알릭스 테라퓨틱스, 인크.
예일 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알릭스 테라퓨틱스, 인크., 예일 유니버시티 filed Critical 알릭스 테라퓨틱스, 인크.
Publication of KR20250008042A publication Critical patent/KR20250008042A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020247034686A 2022-03-22 2023-03-22 Mglur5 조정 화합물, 조성물, 및 사용 방법 Pending KR20250008042A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263322446P 2022-03-22 2022-03-22
US63/322,446 2022-03-22
PCT/US2023/015966 WO2023183428A1 (en) 2022-03-22 2023-03-22 Mglur5 modulating compounds, compositions, and methods of use

Publications (1)

Publication Number Publication Date
KR20250008042A true KR20250008042A (ko) 2025-01-14

Family

ID=88101942

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247034686A Pending KR20250008042A (ko) 2022-03-22 2023-03-22 Mglur5 조정 화합물, 조성물, 및 사용 방법

Country Status (9)

Country Link
US (1) US20250230149A1 (https=)
EP (1) EP4496572A4 (https=)
JP (1) JP2025509988A (https=)
KR (1) KR20250008042A (https=)
CN (1) CN119300827A (https=)
AU (1) AU2023238896A1 (https=)
CA (1) CA3246263A1 (https=)
IL (1) IL315809A (https=)
WO (1) WO2023183428A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025080252A1 (en) * 2023-10-13 2025-04-17 Allyx Therapeutics, Inc. Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
WO2025188734A1 (en) * 2024-03-06 2025-09-12 Allyx Therapeutics, Inc. Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691821B2 (en) * 2010-11-11 2014-04-08 Bristol-Myers Squibb Company Oxazolidinones as modulators of mGluR5

Also Published As

Publication number Publication date
WO2023183428A8 (en) 2023-12-14
AU2023238896A1 (en) 2024-10-03
CA3246263A1 (en) 2023-09-28
EP4496572A1 (en) 2025-01-29
US20250230149A1 (en) 2025-07-17
CN119300827A (zh) 2025-01-10
JP2025509988A (ja) 2025-04-11
EP4496572A4 (en) 2026-03-11
WO2023183428A1 (en) 2023-09-28
IL315809A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
US10584122B2 (en) Solid forms of a compound modulating kinases
JP6381016B2 (ja) 選択的ｃｄｋ４／６阻害剤の固体形態
KR20250008042A (ko) Mglur5 조정 화합물, 조성물, 및 사용 방법
IL268092B2 (en) Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
JP2023107900A (ja) 標的治療剤
KR20260026542A (ko) 포시펜 d-타르트레이트의 고체 형태
CA2574920A1 (en) Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate
US20210347758A1 (en) Crystalline Forms of Niraparib Freebase
KR20240054333A (ko) 공결정
JP2021525758A (ja) 膀胱がんの治療のための方法
JP2005511639A (ja) 虚血性疾患の治療用ドパミン再取り込み阻害活性を有するトロパン誘導体
WO2025188734A1 (en) Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
WO2025080252A1 (en) Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
AU2023468841A1 (en) Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
KR102399374B1 (ko) 알츠하이머병의 치료를 위한 ｎ-[2-(6-플루오로-1ｈ-인돌-3-일)에틸]-3-(2,2,3,3-테트라플루오로프로폭시)벤질아민 히드로클로라이드의 신규한 다형체 형태
US12589090B2 (en) Compounds and methods for the treatment of degenerative disorders
KR102065236B1 (ko) 속방형 덱사메타손 및 서방형 온단세트론을 포함하는 1일 1회 복합 구강 속붕해정 및 이의 제조방법
WO2024027752A1 (zh) 包含杂环化合物的药物组合物及其制备方法和应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000